OnCo

Retinoblastoma: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Screening, prevention and diagnosis1
Advanced, first line2
Second line1

Screening, prevention and diagnosis

SubgroupSettingApproachProducts and trialsEvidence
All comersSurveillance and geneticsSerial examinations under anaesthesia until ~7 years; germline RB1 testing; screening of at-risk relatives from birth; lifelong second-cancer awareness in carriers.40

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersAdvanced unilateral (group E, no vision potential)Primary enucleation with long optic nerve segment; adjuvant chemotherapy (VEC) for high-risk pathology; orbital implant.81
All comersExtraocular / metastaticIntensive multi-agent chemotherapy with autologous stem-cell rescue; radiotherapy to orbit; CNS disease has poor prognosis.91

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersEye-salvage (groups B-D, bilateral)Intra-arterial melphalantopotecan, carboplatin) via ophthalmic artery, or systemic chemoreduction (vincristine, etoposide, carboplatin) with consolidating laser, cryotherapy or plaque brachytherapy; intravitreal melphalan for vitreous seeds.85

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.